Thr74

Site Information
sDEEREPtPVLGsGA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 451477
Associated spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 )
Disease tissue studied:	breast cancer ( 5 , 11 , 12 , 25 , 26 ) , breast ductal carcinoma ( 11 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 11 ) , cervical cancer ( 67 ) , cervical adenocarcinoma ( 67 ) , gastric cancer ( 33 , 34 ) , gastric carcinoma ( 33 , 34 ) , leukemia ( 27 , 32 , 36 , 90 , 91 , 92 ) , acute myelogenous leukemia ( 27 , 32 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 24 , 27 ) , acute megakaryoblastic leukemia (M7) ( 24 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 24 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 24 ) , acute myeloblastic leukemia, without maturation (M1) ( 24 ) , chronic myelogenous leukemia ( 90 , 91 , 92 ) , T cell leukemia ( 36 ) , liver cancer ( 72 ) , hepatocellular carcinoma ( 72 ) , hepatocellular carcinoma, surrounding tissue ( 61 ) , lung cancer ( 8 , 18 , 26 , 42 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 ) , non-small cell lung cancer ( 26 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 ) , non-small cell lung adenocarcinoma ( 8 , 18 , 75 , 76 , 77 , 79 ) , lymphoma ( 13 ) , B cell lymphoma ( 24 ) , Burkitt's lymphoma ( 13 ) , non-Hodgkin's lymphoma ( 24 ) , follicular lymphoma ( 13 ) , mantle cell lymphoma ( 13 ) , neuroblastoma ( 23 ) , ovarian cancer ( 11 ) , pancreatic ductal adenocarcinoma ( 16 ) , multiple myeloma ( 24 , 59 ) , prostate cancer ( 66 ) , salivary gland cancer ( 84 , 85 ) , melanoma skin cancer ( 7 , 69 ) , FTLD ( 47 )
Relevant cell line - cell type - tissue:	'brain, cerebral cortex' ( 47 ) , 'muscle, skeletal' ( 35 ) , 'pancreatic, ductal'-pancreas ( 16 ) , 'stem, embryonic' ( 70 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 52 ) , 293 (epithelial) [AT1 (human), transfection] ( 50 ) , 293 (epithelial) ( 10 , 46 , 53 , 54 , 55 , 56 , 71 ) , 293E (epithelial) ( 39 ) , 786-O (renal) [VHL (human), transfection] ( 6 ) , 786-O (renal) ( 6 ) , A498 (renal) ( 58 ) , A549 (pulmonary) ( 19 , 42 ) , AML-193 (monocyte) ( 24 , 27 ) , B lymphocyte-blood ( 59 ) , BJAB (B lymphocyte) ( 13 ) , breast ( 2 , 11 ) , BT-20 (breast cell) ( 26 ) , BT-474 (breast cell) ( 5 ) , BT-549 (breast cell) ( 26 ) , Calu 6 (pulmonary) ( 26 ) , CMK (megakaryoblast) ( 24 ) , CTS (myeloid) ( 24 ) , DOHH2 ('B lymphocyte, precursor') ( 24 ) , endothelial-aorta ( 28 ) , FL-18 (B lymphocyte) ( 13 ) , FL-318 (B lymphocyte) ( 13 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 29 ) , Flp-In T-Rex-293 (epithelial) ( 29 ) , GM00130 (B lymphocyte) ( 57 ) , H2009 (pulmonary) ( 26 ) , H2077 (pulmonary) ( 26 ) , H2887 (pulmonary) ( 26 ) , H322M (pulmonary) ( 26 ) , HCC1359 (pulmonary) ( 26 ) , HCC1937 (breast cell) ( 26 ) , HCC2279 (pulmonary) ( 26 ) , HCC366 (pulmonary) ( 26 ) , HCC4006 (pulmonary) ( 26 ) , HCC78 (pulmonary) ( 26 ) , HCC827 (pulmonary) ( 26 ) , HEL (erythroid) ( 24 , 27 ) , HeLa (cervical) ( 1 , 9 , 22 , 37 , 41 , 45 , 48 , 60 , 68 , 74 , 83 , 89 , 93 , 94 ) , HeLa S3 (cervical) ( 43 , 67 , 88 ) , hepatocyte-liver ( 61 ) , HepG2 (hepatic) ( 72 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 12 ) , HMLER ('stem, breast cancer') ( 12 ) , HOP62 (pulmonary) ( 26 ) , HUES-9 ('stem, embryonic') ( 44 ) , JEKO-1 (B lymphocyte) ( 13 ) , Jurkat (T lymphocyte) ( 20 , 31 , 38 , 40 , 49 , 51 , 62 , 63 , 64 , 73 , 86 , 87 , 95 , 96 , 97 ) , K562 (erythroid) ( 22 , 68 , 90 , 91 , 92 ) , Kasumi-1 (myeloid) ( 24 ) , KG-1 (myeloid) ( 24 , 32 ) , Kit225 (T lymphocyte) ( 36 ) , LCLC-103H (pulmonary) ( 26 ) , leukocyte-blood ( 65 ) , liver ( 15 , 72 ) , LNCaP (prostate cell) ( 66 ) , LOU-NH91 (squamous) ( 26 ) , lung ( 18 ) , MCF-7 (breast cell) ( 4 , 5 , 26 ) , MDA-MB-231 (breast cell) ( 26 ) , MDA-MB-468 (breast cell) ( 26 ) , MKN-45 (gastric) ( 33 , 34 ) , MV4-11 (macrophage) ( 24 ) , NB10 (neural crest) ( 23 ) , NCEB-1 (B lymphocyte) ( 13 ) , NCI-H1395 (pulmonary) ( 26 ) , NCI-H1568 (pulmonary) ( 26 ) , NCI-H157 (pulmonary) ( 26 ) , NCI-H1648 (pulmonary) ( 26 ) , NCI-H1650 (pulmonary) ( 78 , 80 , 81 , 82 ) , NCI-H1666 (pulmonary) ( 26 ) , NCI-H2030 (pulmonary) ( 26 ) , NCI-H2172 (pulmonary) ( 26 ) , NCI-H2228 (pulmonary) ( 75 , 76 , 77 , 79 ) , NCI-H322 (pulmonary) ( 26 ) , NCI-H460 (pulmonary) ( 26 , 74 ) , NCI-H520 (squamous) ( 26 ) , NCI-H647 (pulmonary) ( 26 ) , NPC (neural crest) ( 23 ) , OCI-ly1 (B lymphocyte) ( 13 ) , OPM-2 (plasma cell) ( 24 ) , ovary ( 11 ) , P31/FUJ (erythroid) ( 24 ) , PANC-1 (pancreatic) [PRP4 (human), knockdown, Lentiviral introduced doxycycline-inducible PRP4 shRNA] ( 17 ) , PANC-1 (pancreatic) ( 17 ) , PC9 (pulmonary) ( 8 , 26 ) , PC9-IR (pulmonary) ( 8 ) , Raji (B lymphocyte) ( 13 ) , RAMOS (B lymphocyte) ( 13 ) , REC-1 (B lymphocyte) ( 13 ) , RL ('B lymphocyte, precursor') ( 24 ) , RPMI-8266 (plasma cell) ( 24 ) , salivary gland ( 84 , 85 ) , SEM (B lymphocyte) ( 98 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 14 ) , SH-SY5Y (neural crest) ( 14 ) , SKBr3 (breast cell) ( 25 ) , skin ( 69 ) , SU-DHL-4 (B lymphocyte) ( 13 ) , SU-DHL-6 (B lymphocyte) ( 24 ) , U266 (plasma cell) ( 24 ) , UPN-1 (B lymphocyte) ( 13 ) , WM239A (melanocyte) ( 7 )

Upstream Regulation
Regulatory protein:	PRP4 (human) ( 17 ) , TBK1 (human) ( 19 )
Treatments:	antibody ( 86 ) , dasatinib ( 68 ) , lapatinib ( 25 ) , LRRK2-IN-1 ( 14 ) , metformin ( 4 ) , nocodazole ( 67 )

References
1	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
4	Sacco F, et al. (2016) Deep Proteomics of Breast Cancer Cells Reveals that Metformin Rewires Signaling Networks Away from a Pro-growth State. Cell Syst 2, 159-71 27135362 Curated Info
5	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
6	Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72 26506913 Curated Info
7	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
8	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
9	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
10	Wang R, et al. (2014) Global discovery of high-NaCl-induced changes of protein phosphorylation. Am J Physiol Cell Physiol 307, C442-54 24965592 Curated Info
11	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
12	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
13	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
14	Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76 24117733 Curated Info
15	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
16	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
17	Gao Q, et al. (2013) Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approaches. J Biol Chem 288, 30125-38 24003220 Curated Info
18	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
19	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
20	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
21	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
22	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
23	DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513 24349301 Curated Info
24	Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37 23628362 Curated Info
25	Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57 22964224 Curated Info
26	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
27	Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66 22547687 Curated Info
28	Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81 22497526 Curated Info
29	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
30	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
31	Mulhern D (2012) CST Curation Set: 13109; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
32	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
33	Mulhern D (2012) CST Curation Set: 13402; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
34	Mulhern D (2012) CST Curation Set: 13405; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
35	Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876 22673903 Curated Info
36	Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91 21722762 Curated Info
37	Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540 21857030 Curated Info
38	Mulhern D (2011) CST Curation Set: 12680; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
39	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
40	Guo A (2011) CST Curation Set: 11893; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
41	Guo A (2011) CST Curation Set: 11453; Year: 2011; Biosample/Treatment: cell line, HeLa/nocodazole &'\|\|' pervanadate; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (STP) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (STP) Immunoaffinity Beads Cat#: 5756 Curated Info
42	Yu G, et al. (2011) Phosphoproteome profile of human lung cancer cell line A549. Mol Biosyst 7, 472-9 21060948 Curated Info
43	Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457 20860994 Curated Info
44	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
45	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
46	Goswami T, Ballif B. (2011) Methods for the Isolation of Phosphoproteins and Phosphopeptides for Mass Spectrometry Analysis: Toward Increased Functional Phosphoproteomics Curated Info
47	Herskowitz JH, et al. (2010) Phosphoproteomic Analysis Reveals Site-Specific Changes in GFAP and NDRG2 Phosphorylation in Frontotemporal Lobar Degeneration. J Proteome Res 9, 6368-79 20886841 Curated Info
48	Zhou J (2010) CST Curation Set: 10712; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (STP) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (STP) Immunoaffinity Beads Cat#: 5756 Curated Info
49	Possemato A (2010) CST Curation Set: 10722; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
50	Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304 20686112 Curated Info
51	Possemato A (2010) CST Curation Set: 10139; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
52	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
53	Guo A (2010) CST Curation Set: 6268; Year: 2010; Biosample/Treatment: cell line, 293/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
54	Guo A (2010) CST Curation Set: 6269; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
55	Guo A (2010) CST Curation Set: 6270; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
56	Guo A (2010) CST Curation Set: 6271; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
57	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info
58	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
59	Ge F, et al. (2010) Phosphoproteomic analysis of primary human multiple myeloma cells. J Proteomics 73, 1381-90 20230923 Curated Info
60	Zhou J (2010) CST Curation Set: 9270; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS Curated Info
61	Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9 20166139 Curated Info
62	Possemato A (2010) CST Curation Set: 9155; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
63	Possemato A (2010) CST Curation Set: 9156; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
64	Possemato A (2010) CST Curation Set: 9157; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
65	Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32 20058876 Curated Info
66	Chen L, Giorgianni F, Beranova-Giorgianni S (2010) Characterization of the phosphoproteome in LNCaP prostate cancer cells by in-gel isoelectric focusing and tandem mass spectrometry. J Proteome Res 9, 174-8 20044836 Curated Info
67	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
68	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
69	Tucker M (2009) CST Curation Set: 8371; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
70	Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13 19664994 Curated Info
71	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
72	Lee HJ, et al. (2009) Quantitative analysis of phosphopeptides in search of the disease biomarker from the hepatocellular carcinoma specimen. Proteomics 9, 3395-408 19562805 Curated Info
73	Possemato A (2009) CST Curation Set: 6851; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
74	Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74 19415658 Curated Info
75	Possemato A (2009) CST Curation Set: 6439; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/control; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
76	Possemato A (2009) CST Curation Set: 6440; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
77	Possemato A (2009) CST Curation Set: 6454; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
78	Possemato A (2009) CST Curation Set: 6455; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
79	Possemato A (2009) CST Curation Set: 6452; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/control; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
80	Possemato A (2009) CST Curation Set: 6437; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/control; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
81	Possemato A (2009) CST Curation Set: 6450; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/control; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
82	Possemato A (2009) CST Curation Set: 6438; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
83	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info
84	Stokes M (2009) CST Curation Set: 6212; Year: 2009; xenograft, Biosample/Treatment: tissue, salivary gland/untreated; Disease: salivary gland cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
85	Stokes M (2009) CST Curation Set: 6211; Year: 2009; xenograft, Biosample/Treatment: tissue, salivary gland/untreated; Disease: salivary gland cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
86	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
87	Possemato A (2008) CST Curation Set: 5276; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
88	Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48 18691976 Curated Info
89	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
90	Stokes M (2008) CST Curation Set: 4388; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
91	Stokes M (2008) CST Curation Set: 4391; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
92	Stokes M (2008) CST Curation Set: 4394; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
93	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info
94	Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51 18220336 Curated Info
95	Stokes M (2008) CST Curation Set: 3882; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
96	Stokes M (2008) CST Curation Set: 3884; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
97	Stokes M (2008) CST Curation Set: 3886; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
98	Moritz A (2006) CST Curation Set: 1831; Year: 2006; Biosample/Treatment: cell line, SEM/-; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info